IBI311 IGF-1R Antibody to Evaluate Efficacy, Safety in Inactive Moderate-to-Severe Thyroid Eye Disease
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Abstract
A clinical study will evaluate the efficacy and safety of IBI311, a fully human IGF-1R inhibitory antibody, for treating inactive moderate-to-severe thyroid-associated ophthalmopathy (TAO).
